



## PORTFOLIO ACTIVITY & ATTRIBUTION

### Christina Malbon, CFA, Assistant Portfolio Manager

During the fourth quarter of 2025, the Patient Opportunity Trust generated a total return of 6.37% net of fees. In comparison, the Fund's unmanaged benchmark index, the S&P 500 Index, returned 2.66%.

Using a three-factor performance attribution model, allocation, selection, and interaction effects contributed to the portfolio's outperformance.

**Alphabet Inc. (GOOGL)**, **Precigen (PGEN)**, **Illumina Inc. (ILMN)**, **Citigroup Inc. (C)**, and **General Motors (GM)** were the largest contributors to performance, while **Coinbase Global Inc. (COIN)**, **Fiserv Inc. (FI)**, **Fidelity Wise Origin Bitcoin Fund (FBTC)**, **Alibaba Group Holdings Ltd. (BABA)**, and **Meta Platforms Inc. (META)** were the largest detractors.

Relative to the index, the Fund was overweight the Consumer Discretionary, Communication Services, Financials, Energy, Industrials, and Health Care sectors on average during the quarter. With zero allocation to Real Estate, Utilities, Materials, and Consumer Staples, the Fund was underweight these sectors along with Information Technology.

The portfolio entered three new positions, **Biogen Call Options (C150 1/21/28)**, **Chime Financial Inc. (CHYM)**, and **Fiserv Inc. (FI)** and exited one position, **Angi Inc. (ANGI)** during the quarter.

The portfolio ended the quarter with 38 holdings where the top 10 stocks represented 54.9% of total assets compared to 39.2% for the index, highlighting the Fund's meaningful active share of around 91.7%.

## Portfolio Review

The market finished another strong year, posting returns of 17.88% and marking the seventh best three-year period in market history. 2025 was the year of AI, with beneficiaries spanning hardware, energy, and component suppliers across the ecosystem. Seven stocks<sup>1</sup> represented more than half the S&P 500's returns, creating a challenging environment for active managers. Despite this, our Fund performed well, outperforming the S&P 500 for the third consecutive year with a return of 27.73%.

What may be more surprising is that our top sector contributor was Health Care, only the sixth best performing sector in the S&P 500. We often describe ourselves as bottom-up stock pickers focused on idiosyncratic opportunities, and this is exactly what we mean, strong returns coming from non-obvious places.

Less surprising, in hindsight, is that Health Care was our worst performing sector last year. We began adding exposure in early 2024, finding attractive value as the sector traded near historically low valuations. While it was painful at the time to reinvest gains into names that continued to underperform, that discipline paid off this year as those positions rebounded sharply. We still see additional upside ahead.

Several holdings drove this performance. **Precigen Inc. (PGEN)** was a standout performer as the PIPE (Private Investment in Public Equity) we led last December helped the company reach FDA approval for its lead RRP (recurrent respiratory papillomatosis) drug. We continue to see attractive assets across the pipeline that we believe remain underappreciated. **CVS Health Corp. (CVS)** rebounded as the company improved underwriting discipline in its Medicare Advantage business and delivered better financial results. **Royalty Pharma (RPRX)**, a business that remains misunderstood, simplified its operating structure through the acquisition of its external manager, aligning management more closely with shareholders, and continued to originate attractive royalty transactions. **UnitedHealth Group**

<sup>1</sup> The seven stocks that represented more than half of the S&P 500's returns were NVDA, GOOGL, MSFT, AVGO, JPM, PLTR and META.

Returns referenced are for the Class I share as of quarter end 12/31/25.

Gross (Net) Expenses (%): Class A 1.76 (1.74); Class C 2.53 (2.52); Class FI 1.83 (1.82); Class I 1.52 (1.48); Class IS 1.44 (1.42); Class R 2.02 (2.01).

Performance shown represents past performance and is no guarantee of future results. Current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so shares, when redeemed, may be worth more or less than the original cost. Total returns assume the reinvestment of all distributions at net asset value and the deduction of all Fund expenses. Performance would have been lower if fees had not been waived in various periods. For the most recent month-end information, please visit [patientcapitalmanagement.com/opportunity-trust](https://patientcapitalmanagement.com/opportunity-trust).

### Top Ten by Issuer as of 12/31/25

Name	% of Portfolio
Alphabet Inc.	7.6
Precigen, Inc.	6.4
Citigroup Inc.	6.3
Amazon.com, Inc.	5.5
Royalty Pharma plc	5.2
QXO, Inc.	5.2
Nvidia Corp	5.0
UnitedHealth Group	4.9
Norwegian Cruise Line Holdings Ltd.	4.8
Meta Platforms, Inc.	4.0
<b>Total</b>	<b>54.9%</b>



**Inc. (UNH)** was added following its steep sell-off in April. Knowing the business well, we saw a clear path to improved results and took advantage of the dislocation. While the rebound was faster than expected, we believe there remains room for further improvement. Finally, late in the year **Biogen Inc (BIIB)**, a long-held position, began to show signs of recovery as confidence improved around its late-stage pipeline and optimism increased around the Alzheimer's opportunity as blood-based biomarkers and subcutaneous formulations come to market.

While we held names that benefited from the AI evolution, we continue to generate the majority of our outperformance from unique, idiosyncratic ideas. What we do best.

## New and Eliminated

This quarter we entered three new positions and exited one position. We increased our exposure to **Biogen Inc. (BIIB)** in the quarter by buying long-dated call options expiring in 2028 with a strike price of \$150. We continue to think Biogen is an attractive asset over the long term. The company has a number of late-stage pipeline assets that should reach the market over the next few years, at the same time that its Alzheimer's franchise should continue to ramp as blood-based biomarkers and subcutaneous injections broaden the potential treatable universe. Longer term, we believe Biogen is positioning itself to own multiple stages of the Alzheimer's disease lifecycle, similar to its historical approach in multiple sclerosis. With a cleaned-up cost structure, a more focused research effort, and a growing late-stage pipeline, we continue to view the risk/reward as attractive.

We built up a small position in **Fiserv Inc. (FI)**, a name we know well, as the company traded down from its peak in early March as topline growth disappointed. Fiserv is a name we previously owned and exited successfully in late 2024. The company is a leader in the payments space, and our original investment was based on the belief that the market was underappreciating its ability to continue gaining share while improving margins. We think today's pullback has created a similar setup. Following the appointment of a new CEO, a complete reset of guidance, and a renewed focus on a client-first culture, we believe the company is well positioned to rebuild investor confidence and return to delivering double-digit EPS growth by 2027.

We built a position in **Chime Financial Inc. (CHYM)**, a recently public fintech focused on providing a low-cost banking alternative to historically underserved consumers. The platform boasts best-in-class engagement and presents a large cross-sell opportunity as it continues to expand beyond its original debit offering. While the company is growing its credit and liquidity products, the majority of its offerings remain tied to direct deposit relationships, which helps limit the amount of credit risk being taken on. With a large and fragmented addressable market, improving monetization through higher product attach rates, and a path to GAAP (Generally Accepted Accounting Principles) profitability over the next year, we believe Chime is well positioned to compound value over time despite near-term investor focus on credit trends.

We exited **Angi Inc. (ANGI)** in the period using the proceeds to invest in new ideas.

## Top Contributors & Top Detractors\*

Top Contributors	Ticker	Return	Contrib.
Alphabet Inc.	GOOGL	28.12	1.93
Precigen, Inc.	PGEN	26.94	1.01
Illumina, Inc.	ILMN	38.11	0.92
Citigroup Inc.	C	15.61	0.88
General Motors Co.	GM	33.16	0.72
Top Detractors	Ticker	Return	Contrib.
Coinbase Global, Inc.	COIN	-32.91	-0.80
Fiserv, Inc.	FI	-46.42	-0.72
Fidelity Wise Origin Bitcoin Fund	FBTC	-23.39	-0.70
Meta Platforms, Inc.	META	-10.04	-0.48
Alibaba Group Holding Ltd.	BABA	-17.98	-0.48

\*Contribution and returns provided above are presented gross of fees and includes cash. For full performance of the Fund, please refer to the full performance information that follows the commentary below. Fund holdings are subject to change. For current fund holdings, click [here](#).



## Top Contributors

- **Alphabet Inc. (GOOGL)** was a top contributor in the fourth quarter, continuing its upward trajectory on successively strong AI launches and gaining 28.1% in the period. We started the year with the prevailing narrative that Alphabet was an AI laggard and are now ending the year with the company firmly in the winner camp. We have long believed the market was underappreciating Google's strong technology and AI advantages, with its Gemini model being integrated across search, YouTube advertising, and its cloud offering. We continue to believe that Google is well positioned to take advantage of the AI revolution. We see additional upside as Google is uniquely positioned to monetize advances at scale. Despite the strong move, we continue to find the company attractive when considering all its market-leading assets.
- **Precigen Inc. (PGEN)** continued to be a top contributor to the Fund following the early approval of Papziemos for the treatment of recurrent respiratory papillomatosis (RRP) in early August. With this approval, Papziemos became the first-in-class "off-the-shelf" immunotherapy for a patient population with no other treatment options. As the company moves quickly to launch the drug, it inches closer to self-funding allowing it to advance its other pipeline assets toward approval. The company is led by Dr. Helen Sabzevari, who brings extensive expertise in immunotherapy-based therapeutics, having founded and served as Chief Scientific Officer of Compass Therapeutics. She has driven remarkable clinical progress at Precigen over the past few years, and we expect her to apply a similar playbook to their other pipeline assets in Phase 2 and Phase 1/1b development. We still see attractive upside given multiple blockbuster assets in development.
- **Illumina Inc. (ILMN)** was a top contributor during the quarter following a stronger-than-expected third quarter earnings report. The company surprised to the upside with a meaningful beat and raise, supported by continued momentum in clinical consumables, which grew faster than expectations as the transition to the high-throughput NovaSeq X continues ramp. We believe that Illumina's core sequencing business is returning to a more normalized growth and profitability profile following several years of disruption. As confidence improves around the durability of demand and margin recovery, we believe the market is beginning to better appreciate the earnings power of the company's market-leading platform.

## Top Detractors

- **Coinbase Global Inc. (COIN)** was a top detractor during the quarter as crypto-related equities followed digital asset prices lower. While price action weighed on results this quarter, we view the move as largely cyclical. Over the long term, we continue to believe Coinbase is evolving beyond a pure crypto trading venue into a broader, scaled financial exchange. As the platform expands into adjacent products including their own layer-2 blockchain known as Base, equity trading, ETF trading, stable coins and prediction markets, we believe Coinbase is positioning itself as a one-stop destination for a new generation of traders and investors. Coupled with the continued maturation of the digital asset ecosystem, increasing institutional participation, and broader adoption, we see this expanding product set supporting greater engagement, diversification of revenues, and attractive long-term earnings power as activity normalizes.
- **Fiserv Inc. (FI)** was a top detractor during the quarter following a significant reset under the company's new CEO. Shortly after taking the helm, management lowered full-year earnings guidance and announced a broad overhaul of its board and senior leadership team as part of a comprehensive reassessment of the business. This led to a sharp market reaction and several sell-side downgrades. While the magnitude of the guidance reduction weighed heavily on near-term sentiment, we continue to believe Fiserv is a leader in the payments space with a scaled, mission-critical platform and deeply embedded customer relationships. As the company works through the reset and reorients the organization around a client-first culture, we believe Fiserv remains well positioned to rebuild investor confidence, resume share gains, and return to delivering double-digit EPS growth by 2027.
- **Fidelity Wise Origin Bitcoin Fund (FBTC)** was a detractor during the quarter as Bitcoin traded lower alongside broader crypto markets. While near-term price action weighed on results this quarter, our long-term view remains unchanged. As Bitcoin becomes more easily accessible, demand should increase while the supply of Bitcoin will continue to be limited at 21M.



Performance Attribution Analysis	Patient Opportunity Trust		S&P 500		Management Effect			Total
	Weight	Return	Weight	Return	Allocation	Selection	Interaction	
<b>Equity - Long Positions</b>	<b>107.68</b>	<b>6.19</b>	<b>100.00</b>	<b>2.66</b>	<b>2.27</b>	<b>1.44</b>	<b>-0.06</b>	<b>3.66</b>
Communication Services	15.26	11.87	10.30	7.26	0.24	0.47	0.23	0.94
Consumer Discretionary	23.99	2.20	10.38	0.71	-0.25	0.17	0.15	0.07
Consumer Staples	0.00	0.00	4.82	0.01	0.13	-0.01	0.01	0.13
Energy	7.59	4.37	2.84	1.53	-0.05	0.09	0.12	0.17
Financials	15.19	1.38	13.21	2.02	-0.02	-0.03	-0.11	-0.16
Health Care	27.89	12.86	9.39	11.68	1.71	0.13	0.08	1.92
Industrials	10.08	9.27	8.15	0.88	-0.01	0.74	0.13	0.86
Information Technology	5.11	-0.04	34.98	1.42	0.35	-0.21	0.12	0.27
Materials	0.00	0.00	1.71	1.12	0.03	-0.01	0.01	0.03
Real Estate	0.00	0.00	1.87	-2.86	0.11	0.06	-0.06	0.11
Utilities	0.00	0.00	2.35	-1.40	0.10	0.03	-0.03	0.10
Cryptocurrency	2.58	-23.39	0.00	0.00	-0.06	0.00	-0.71	-0.77
<b>Cash*</b>	<b>-7.68</b>	<b>-1.92</b>	<b>0.00</b>	<b>0.00</b>	<b>0.20</b>	<b>0.00</b>	<b>0.16</b>	<b>0.35</b>
<b>Total</b>	<b>100.00</b>	<b>6.67</b>	<b>100.00</b>	<b>2.66</b>	<b>2.47</b>	<b>1.44</b>	<b>0.10</b>	<b>4.01</b>

\*Cash holdings are gross of fees.

Market Proxy is S&P 500. Returns greater than 1 year are annualized. Source: Bloomberg and Patient Capital Management.

The data provided is from APX and Patient Capital Management, LLC and is believed to be reliable, but is not guaranteed as to its timeliness or accuracy. Percentages and returns may not sum to 100% due to rounding effects. A three-factor attribution consists of the allocation effect, selection effect, and the interaction effect, which sum to the portfolio's performance relative to the benchmark.

- **Allocation.** The allocation effect represents the portion of the portfolio's excess return attributable to differences in sector weights between the portfolio and the benchmark index.
- **Selection.** The selection effect represents the portion of the portfolio's excess return attributable to differences in the weights of individual securities within each sector between the portfolio and the benchmark index.
- **Interaction.** Most complex and sometimes counterintuitive, the interaction effect represents the portion of the portfolio's excess return attributable to combining sector allocation decisions with security selection decisions, and is often thought of as measuring the accuracy of manager's convictions.

Please note that the methodology used by our independent third-party attribution software vendor will at times present sector allocation effects that are counterintuitive. For example, the software may calculate a negative sector effect even when the portfolio, on a weighted average basis for the period, overweight an outperforming sector. Under the vendor's methodology, allocation effects in recent months may overwhelm the allocation effects from earlier in the period, particularly over longer time frames.

Returns illustrated above are provided net of fees and include cash. Total portfolio return figures provided above reflect the sum of the returns of the holdings in the representative account portfolio due to price movements and dividend payments or other sources of income.

## CONTACT

### Advisor Services

443.652.4225 | [info@patientcm.com](mailto:info@patientcm.com)

[patientcapitalmanagement.com/opportunity-trust](https://patientcapitalmanagement.com/opportunity-trust)

## PATIENT CAPITAL MANAGEMENT

Patient Capital Management LLC is an SEC registered investment advisor founded in 2020 by Samantha McLemore, majority owner and Chief Investment Officer. Formerly operating with Miller Value Partners, Patient Capital acquired the Opportunity Equity business in May 2023 in a transaction completing Bill Miller's succession plan. As of 12/31/25, Patient Capital operates independently managing \$2.5B in assets featuring opportunistic, long-term, value-oriented equity strategies. The Firm is supported by a team of 10 professionals. Bill Miller remains a minority owner and adviser.



Click [here](#) for Patient Opportunity Trust standardized performance.

The **S&P 500 Index (SPX)** is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. **Earnings per share (EPS)** is the portion of a company's profit allocated to each outstanding share of common stock and serves as an indicator of a company's profitability. **Price to earnings** is the market price per share divided by earnings per share. **Active share** is a measure of the percentage of stock holdings in a manager's portfolio that differs from the benchmark index.

**Earnings growth is not a measure of future performance.**

**Equity securities are subject to price fluctuation and possible loss of principal. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. Real estate investment trusts (REITs) are closely linked to the performance of the real estate markets. REITs are subject to illiquidity, credit and interest rate risks, and risks associated with small and mid-cap investments. The Fund may focus its investments in certain regions or industries, increasing its vulnerability to market volatility. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. Derivatives, such as options and futures, can be illiquid, may disproportionately increase losses, and have a potentially large impact on Fund performance. The manager's investment style may become out of favor and/or the manager's selection process may prove incorrect, which may have a negative impact on the Fund's performance. Short selling is a speculative strategy. Unlike the possible loss on a security that is purchased, there is no limit on the amount of loss on an appreciating security that is sold short.**

The Fund has utilized indirect exposure in cryptocurrencies through the holding of the Fidelity Wise Bitcoin Trust (FBTC). Bitcoin and other cryptocurrencies are a relatively new asset class and are subject to unique and substantial risks. Bitcoin is a highly speculative asset that has experienced periods of extreme volatility and may encounter future regulatory changes that may adversely affect its value. Bitcoin is not backed by any government agency.

The views expressed in this commentary reflect those of Patient Capital Management portfolio managers and analysts as of the date of the commentary. Any views are subject to change at any time based on market or other conditions, and Patient Capital Management disclaims any responsibility to update such views. These views are not intended to be a forecast of future events, a guarantee of future results or investment advice. Because investment decisions are based on numerous factors, these views may not be relied upon as an indication of trading intent on behalf of any portfolio. Any data cited herein is from sources believed to be reliable but is not guaranteed as to accuracy or completeness.

The information presented should not be considered a recommendation to purchase or sell any security and should not be relied upon as investment advice. It should not be assumed that any purchase or sale decisions will be profitable or will equal the performance of any security mentioned. References to specific securities are for illustrative purposes only. Portfolio composition is shown as of a point in time and is subject to change without notice.

All historical financial information is unaudited and shall not be construed as a representation or warranty by us. References to indices and their respective performance data are not intended to imply that the Fund's objectives, strategies or investments were comparable to those of the indices in technique, composition or element of risk nor are they intended to imply that the fees or expense structures relating to the Fund or its affiliates, were comparable to those of the indices; since the indices are unmanaged and cannot be invested in directly. Returns for periods greater than one year are annualized. References to specific securities are for illustrative purposes only. Portfolio composition is shown as of a point in time and is subject to change without notice.

The performance information depicted herein is not indicative of future results. There can be no assurance that The Fund's investment objectives will be achieved and a return realized. **Past performance is no guarantee of future results.**

Contributors detailed above represent the top five securities that contributed positively to performance during the quarter. Detractors detailed above represent the top five securities that detracted from performance during the quarter. Information detailed above is provided gross of fees and includes cash. Contribution listed above represents the period when the security was held during the quarter. For additional information on how Top Contributors and Top Detractors were determined and/or to obtain a list showing every holding's contribution to the representative Opportunity Equity account performance contact us.

The information presented should not be considered a recommendation to purchase or sell any security and should not be relied upon as investment advice. It should not be assumed that any purchase or sale decisions will be profitable or will equal the performance of any security mentioned.

Any third party links, trademarks, service marks, logos and trade names included in the report are property of their respective owners. The inclusion of third party link is provided for reference and does not imply endorsement or, association with the site or party by us.

The Patient Opportunity Trust is distributed by Quasar Distributors, LLC.

***Before investing, carefully consider a Fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus if available, which is available at [patientcapitalmanagement.com/opportunity-trust](http://patientcapitalmanagement.com/opportunity-trust). Please read it carefully.***

©2026 Patient Capital Management, LLC